Reprints and Permissions

Article

REPRINTS
For article reprints, please contact:
Wrights Reprints
Phone: (877) 652-5295
Email: sales@wrightsreprints.com

PERMISSIONS
Maureen Cannon
Email: mcannon@advanstar.com

Recent Videos
5 experts in this video
5 experts in this video
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Related Content
Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer

Roman Fabbricatore
March 23rd 2025
Article

Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
March 24th 2025
Podcast

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC

Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC

Tim Cortese
March 22nd 2025
Article

In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Most recently, the FDA accepted a second NDA for camrelizumab/rivoceranib as a treatment for patients with unresectable HCC in October 2024.

FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma

Roman Fabbricatore;Russ Conroy
March 21st 2025
Article

The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.

FDA Approves PET Imaging Agent for Prostate Cancer

FDA Approves PET Imaging Agent for Prostate Cancer

Ariana Pelosci
March 21st 2025
Article

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.